FeesSafety
Pluang+

BridgeBio's Attruby revenue jumps 134% YoY; FDA decision on BBP-418 due Nov 27

Company Fundamentals
22 Nov 2026, 23:15 WIB
The Motley Fool
View Source
Bullish
BridgeBio's Attruby revenue jumps 134% YoY; FDA decision on BBP-418 due Nov 27

BridgeBio reported a 134% year-over-year increase in net product revenue for Attruby, reaching $253.2 million in Q3 2026, driven by new patient starts and real-world evidence of reduced hospitalizations. The company anticipates an FDA decision on BBP-418, a treatment for limb-girdle muscular dystrophy type 2I, by November 27, 2026. Additionally, priority reviews for infigratinib and encaleret could lead to new rare disease therapy launches in 2027. With $1.5 billion in cash and securities, BridgeBio is positioned to support these launches and aims for margin expansion toward breakeven next year.

BridgeBio Pharma Inc trades at USD 76.03 on Pluang as of Nov 23, 2026 04:31 WIB, down 2.75% in one day. The stock's market cap is $14.81 billion, with a 52-week high of $90.17 and low of $63.30. Investors typically hold BBIO for 65 days on the platform, reflecting moderate trading activity amid ongoing developments in rare disease therapies.

More News (BBIO)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App